Northern Breast Cancer Forum 2026 | Professor Peng Yuan: Driving Clinical Transformation Through “Three New Forces” and Anticipating Key Updates in the 2026 CSCO Breast Cancer Guidelines
As China’s flagship academic event in breast cancer at the start of each year, the Northern Breast Cancer Forum continues to bridge global scientific advances with localized clinical practice. From the SERENA-6 trial, which pioneers molecular monitoring for endocrine resistance, to the rapid rise of Trop-2–targeted ADCs and expanded access to PI3K/AKT/mTOR pathway inhibitors under national insurance coverage, the past year has witnessed profound shifts in breast cancer management.

